MATTERS ARISING

A population-based study of syphilis and sexually transmitted diseases in north-western Tanzania

The rationale for improved sexually transmitted disease (STD) facilities in rural Africa as a means of slowing the spread of HIV presupposes that STDs are currently managed poorly and that this is a result of inadequate infrastructure. The finding of Moshu et al1 that "in Mwanza Region [Tanzania], active syphilis seems to be more prevalent than the treated infection" at first glance provides strong support for the argument that money should be invested urgently in improved facilities for diagnosis and treatment. However, as is common practice (and I have been guilty myself) active syphilis is defined as being RPR + TPHA + without quoting titles for the nontreponemal test. If such data were presented a different picture might emerge with a large number of individuals with low titre who can not be labelled as having an "active" infection with any certainty. A treated individual with a fall in titre from high levels to low levels is regarded as successfully treated unless, on follow up, the titre rises again. Thus a cross-sectional survey can never strictly speaking give the percentage of "active" syphilis and may only do so by choosing some arbitrary cut off, usually 1/8 titre.

Unless evidence obtained locally suggests otherwise, it should not be concluded that clinically diagnosed cases of early syphilis are inadequately treated in rural Africa. The treatment is cheap and readily available in most areas. Indeed all STD presentations tend to be treated with benzathine penicillin.2 In my own field work in Uganda in the year the civil war ended, when services were maximally disrupted, only five of 36 TPHA positive outpatients were VDRL positive.3 As in Tanzania4 non-venereal syphilis and yaws are unlikely to have played a role. The reason that those rare individuals are labelled as having active syphilis in serological surveys is strengthened by the fact that the highest rate of "active" syphilis in the Mwanza study was in those with an ulcer in the last year.4 Successful treatment may fail to render a patient negative for nontreponemal tests in the first year of follow up particularly if patients present late.

With the advent of HIV a spuriously high rate of "active" syphilis may occur owing to a slower response of the titres to therapy in HIV positive individuals5 or by the use of only one benzathine penicillin injection when perhaps three weekly injections should have been used.6 In Mwanza, HIV is common and HIV infection is associated with positive serology for syphilis.7 All things being equal, HIV patients with adequately treated syphilis are more likely to be RPR positive than their adequately treated HIV seronegative counterparts. In a recent Zimbabwe study there was a significantly higher prevalence of HIV and syphilis co-infection.8 In conclusion, now more than ever, serological surveys of syphilis in Africa should always give the breakdown of titres of whichever nontreponemal test is used.


Opportunistic cervical cytology screening in a genitourinary department: is it worthwhile?

We read with interest the recent correspondence from Dhur and colleagues discussing the value of opportunistic cervical cytological screening based on their case note review of 200 new genitourinary medicine (GUM) clinic attenders.1 Unfortunately their policy for cervical cytology screening was not stated and it was unclear whether all new female attenders were screened or whether there was any element of selection. There was a further lack of clarity regarding the patients’ previous cytology. Although it was stated that 152 (76%) patients had previously had cytology performed elsewhere, which was normal in 112, no details were given concerning the validation of these data.

The validation of previous cytology at alternative sites is a major problem for all concerned with the introduction of screening programmes and one wonders whether a system of patient held cytology records would be beneficial.

High grade abnormalities of moderate or severe dyskaryosis were found in 12 patients (6%), five of these occurred in women who had never had a cervical smear before. If selected screening had been utilised the five women not previously screened would have had cytology performed and thus the abnormality would have been detected. In the other women moderate dyskaryosis was identified in five and abnormal cytology was found in one; it is not clear how much delay there would have been with selective screening as cytological conversion times were not given in comparison to the subsequent abnormal smears.

No data were given about the prevalence of cytological abnormalities in women attending local family planning clinics, gynaecology outpatients or general practitioners and therefore no conclusions can be drawn about the cytological abnormalities in female GUM clinic attenders compared to other female groups in the area.

There has been much discussion about cervical cytology screening in GUM departments and the prevalence of cytological abnormalities appears to be higher amongst GUM attenders. For instance in a study of new GUM attenders in New Zealand 6% had abnormal smears; only in 6-6% of cases was this attributable to dysplasia or carcinoma in situ; nevertheless this figure was higher than rates seen in a local family planning cohort.2 Elsewhere amongst the GUM attenders in Tanzania have varied from 11-4% for dysplasia and carcinoma in situ in the United States3 and 11-9% in Sri Lanka4 whilst in a United Kingdom GUM clinic, in a study primarily looking for signs of abnormalities of women with abnormal cytology, of the 4520 women screened 227 (5-0%) had mild dyskaryosis, 214 (4-7%) moderate dyskaryosis, 67 (1-5%) severe dyskaryosis.

In view of the risk factors for cervical dysplasia commonly seen in female GUM clinic attenders, such as an early age of coitarche, multiple sexual partners and the presence of human papilloma virus it would seem logical to introduce targeted opportunistic screening. However, the value regarding the ultimate clinical outcome is unproven and it has been suggested that opportunistic screening should be carefully considered with a reduction in the smears screened and an improvement in the CIN detection rate.6 We agree with the need for a large aged matched prospective study to compare cytology in female GUM clinic attenders with other female cohorts. In addition we suggest that there is a greater need to compare cytology, colposcopy and biopsy findings with the final clinical outcome. Only by using this approach will we be able to follow a policy of opportunistic screening is of clinical benefit.

E M CARLIN
S E BARTON
St Stephen’s Clinic, 359 Fulham Rd, London SW6 9TF, UK


1994.